期刊文献+

吉非替尼治疗晚期非小细胞肺癌的临床观察 被引量:3

暂未订购
导出
摘要 肺癌是目前全世界发病率和死亡率最高的恶性肿瘤,其中非小细胞肺癌(non—smallcelllungcancer,NSCLC)占肺癌的80%~85%,其5年生存率〈15%。非小细胞肺癌患者就诊时25%-30%已是局部晚期,40%~50%有远处转移,这类患者无法手术,只能进行放、化疗。常用一线治疗方案是铂类药物联合第三代细胞毒性药物联合化疗,但有效率仅为35%~40%,中位生存期为8—10个月,1年生存率约为35%。
出处 《实用癌症杂志》 2009年第6期652-653,共2页 The Practical Journal of Cancer
  • 相关文献

参考文献10

  • 1Jemal A, Murray T, Samuels A, et al. Cancer statistice,2003 [J]. CA Cancer J Clin,2003,53( 1 ) :5.
  • 2Schmidt M, Maurer-gebhard M, Groner B,et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full length and oncogenic variant EGF receptors [J]. Oncogene, 1999,18(9) :1711.
  • 3Ciardiello F, Caputo R, Bianco R, et al. Inhibiton of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor[J]. Clin Cancer Res ,2001,7 ( 5 ) : 1459.
  • 4Brehmer D, Greff Z, Godl K, et al. Celluar targets of gefitinib [J]. Cancer Res,2005,65 ( 2 ) : 379.
  • 5Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer The IDEAL 1 Trial [J]. J Clin Oncol, 2003,21 (12) :2237.
  • 6Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J]. JAMA,2003,290(16) :2149.
  • 7林丽珊,张力,赵洪云,林立平,吴烜,张阳,管忠震.吉非替尼治疗化疗失败的局部晚期或转移性非小细胞肺癌疗效及生存的预测因素[J].中国肺癌杂志,2007,10(5):411-417. 被引量:10
  • 8王燕,张湘茹,王彬,王子平,储大同,孙燕.吉非替尼治疗69例老年肺腺癌的临床分析[J].中国肺癌杂志,2008,11(1):137-141. 被引量:10
  • 9郑华,王敬萍,孟弃逸,刘赞,李宝兰,朱允中.吉非替尼(Iressa)在晚期肺腺癌的靶向治疗疗效观察[J].中国肺癌杂志,2007,10(3):229-233. 被引量:10
  • 10茅卫东,刘少平,林峰,许晨,王琼,沈伟生.吉非替尼治疗晚期非小细胞肺癌36例临床观察[J].癌症进展,2007,5(6):608-610. 被引量:1

二级参考文献66

  • 1杨鹭,刘叙仪,方健,安彤同,吴梅娜.吉非替尼治疗91例晚期非小细胞肺癌疗效分析[J].中华肿瘤杂志,2006,28(6):474-477. 被引量:36
  • 2[1]Younes RN,Deutsch F,Badra C,et al.Nonsmall cell lung cancer:evaluation of 737 consecutive patients in a single institution.Rev Hosp Clin Fac Med Sao Paulo,2004,59(3):119-127.
  • 3[2]Schiller JH,Harrington D,Belani CP,et al; Eastern Cooperative Oncology Group.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,2002,346(2):92-98.
  • 4[3]Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebocontrolled,multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet,2005,366(9496):1527-1537.
  • 5[4]Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst,2000,92(3):205-216.
  • 6[6]Massarelli E,Andre F,Liu DD,et al.A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.Lung Cancer,2003,39(1):55-61.
  • 7[7]Brehmer D,Greif Z,Godl K,et al.Cellular targets of gefitinib.Cancer Res,2005,65(2):379-382.
  • 8[8]Fukuoka M,Yano S,Giaccone G,et al.Final results from a phase Ⅱ trial of ZD1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1).Proc Am Soc Clin Oncol,2002,21:298a(abstr 1188).
  • 9[9]Kris MG,Natale RB,Herbst RS,et al.A phase Ⅱ trial of ZD1839 (‘ Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2).Proc Am Soc Clin Oncol,2002,21:292a(abstr 1166).
  • 10[10]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial).J Clin Oncol,2003,21(12):2237-2246.

共引文献26

同被引文献43

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部